# Intercept Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/intercept-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Morristown, US
- Website: www.interceptpharma.com
- Total disclosed funding: $55M
- Latest round: Series C (Aug 9, 2012)
- Investors on record: 6

## About

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative treatments for rare liver diseases, primarily targeting primary biliary cholangitis (PBC) through its proprietary drug offerings.Founded in 2002 in Morristown, US, Intercept Pharmaceuticals specializes in the development of therapies for serious liver diseases. The company has undergone strategic shifts in its business operations and was significantly impacted by its acquisition in May 2022 by Advanz Pharma Services (UK) Limited. The company has raised a total of USD 405.00 mn through various funding rounds, including its most recent TRADE SALE on October 11, 2012, where it received USD 405.00 mn from Advanz Pharma Services (UK) Limited. The company is co-founded by Mark Pruzanski, who has a history of leading pharmaceutical ventures.Intercept Pharmaceuticals focuses on developing and delivering innovative treatments for rare and serious liver diseases, with a notable emphasis on primary biliary cholangitis (PBC). The company's core product offerings include Ocaliva (obeticholic acid), the first and only FDA-approved farnesoid X receptor (FXR) agonist for PBC treatment. Ocaliva alleviates inflammation and prevents liver damage by reducing bile acid levels in the liver. The company’s proprietary scientific platforms target key biological pathways associated with liver health, addressing various liver conditions and serving healthcare providers and patients across the US, European Union, Canada, and other international markets.In 2022, Intercept Pharmaceuticals generated revenue amounting to USD 285.71 mn, while reporting an EBITDA of USD -65.65 mn. The company's revenue primarily comes from the sale of Ocaliva to healthcare providers and specialty pharmacies, utilizing a business-to-business model with payments predominantly through insurance reimbursements.Intercept Pharmaceuticals aims to advance its Phase III POISE trial of obeticholic acid, a key treatment for patients unable to tolerate the current approved drug for PBC. The recent funding from Advanz Pharma Services (UK) Limited will be allocated to this trial's continuation and to bolster the company's investigational pipeline. Furthermore, the acquisition is expected to enhance growth opportunities, particularly in the gastroenterology and hepatology sectors, as Intercept seeks to expand its presence in Europe, Canada, and the U.S. through strategic collaborations and partnerships.

## Funding rounds

- Series C, Aug 9, 2012, $30M — OrbiMed Advisors, Aisling Capital, Genextra S.p.A.
- Series A, May 16, 2008, $25M — JAFCO Group, Rodman & Renshaw, Genextra S.p.A., BAM Elevate

## Investors

- JAFCO Group (https://capitalatlas.ai/funds/jafco-group) — Series A
- Rodman & Renshaw — Series A
- Genextra S.p.A. — Series A, Series C
- BAM Elevate (https://capitalatlas.ai/funds/bam-elevate) — Series A
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series C
- Aisling Capital (https://capitalatlas.ai/funds/aisling-capital) — Series C